// App-Quantinova.ai

1304 : Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center

Researchers

Presenter

  • Ofir Wolach

Principal Investigators

  • Kristen Stevenson

  • Martha Wadleigh

  • Daniel J. DeAngelo

  • David P. Steensma

  • Robert J. Soiffer

  • Joseph H Antin

  • Donna S Neuberg

  • Vincent T. Ho

  • Richard M. Stone

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved